• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of neurosurgery >EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers
【24h】

EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

机译：胶质母细胞瘤中的EGFR和EGFRvIII分析作为治疗性生物标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction. EGFR and EGFRvIII analysis is of current interest because of new EGFRvIII vaccine trials opened in the UK. EGFR activation promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways. EGFRvIII is the most common variant resulting from an in-frame deletion of 801 bp, leading to constitutively active EGFR. Method. 51 glioblastoma samples from a cohort of 50 patients were tested for EGFR amplification by FISH and immunohistochemistry and EGFRvIII expression by reverse-transcriptase PCR (RT-PCR), and immunohistochemistry. EGFR and EGFRvIII expression was compared with Overall Survival in the cohort. Results. Overall 22/51 samples (43%) were positive for EGFR, 16/51 (31%) were positive for EGFRvIII and 13/51 (25%) were positive for both. 9/51 cases (18%) were positive for EGFR alone, and 3/51 (6%) were positive for EGFRvIII alone. Of the EGFR positive cases, 22/51 (43%) were positive by FISH, 24/51 (47%) were positive by IHC and 2/51 (4%) were discrepant between methods (positive by IHC but non-amplified by FISH). Of the EGFRvIII positive cases, 16/51 (31%) were positive by RT-PCR, 17/51 (33%) were positive by IHC and 1/51 (2%) sample was discrepant (positive by IHC but not by RT-PCR). Neither EGFRvIII or EGFR are predictive of overall survival in this cohort. Conclusion. In our cohort, 25/51 (49%) of GBM showed EGFR alterations, including 16/51 (31%) with EGFRvIII. There was high concordance between IHC and FISH (96%) and IHC and RT-PCR (98%) as diagnostic methods. Neither EGFR or EGFRvIII is predictive of overall survival in this cohort. These results are key for selecting patients for novel individualised anti-EGFR therapies.
机译：介绍。由于在英国开展了新的EGFRvIII疫苗试验，因此对EGFR和EGFRvIII的分析引起了人们的关注。 EGFR激活通过激活MAPK和PI3K-Akt途径促进细胞增殖。 EGFRvIII是最常见的变异，是由801 bp的框内缺失导致的，从而导致了组成型活性EGFR。方法。通过FISH和免疫组织化学测试了来自50名患者的51个胶质母细胞瘤样品的EGFR扩增，并通过逆转录酶PCR（RT-PCR）和免疫组织化学测试了EGFRvIII的表达。将队列中的EGFR和EGFRvIII表达与总生存期进行比较。结果。总体上22/51个样本（43％）EGFR阳性，16/51（31％）EGFRvIII阳性，13/51（25％）两者均为阳性。 9/51例（18％）仅EGFR阳性，3/51例（6％）EGFRvIII阳性。在EGFR阳性病例中，FISH阳性率为22/51（43％），IHC阳性为24/51（47％），两种方法之间的差异为2/51（4％）（IHC阳性但未扩增）鱼）。在EGFRvIII阳性病例中，RT-PCR阳性率为16/51（31％），IHC阳性为17/51（33％），1/51（2％）样品差异较大（IHC阳性但RT不阳性） -PCR）。 EGFRvIII或EGFR均不能预测该队列的总生存期。结论。在我们的队列中，GBM的25/51（49％）显示EGFR改变，包括EGFRvIII的16/51（31％）。 IHC和FISH（96％）与IHC和RT-PCR（98％）作为诊断方法之间具有很高的一致性。 EGFR或EGFRvIII均不能预测该队列的总体生存。这些结果是选择患者进行新型个体化抗EGFR治疗的关键。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号